​
​

Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?

OverviewForecastRevenueFinancialsChart

Zentalis Pharmaceuticals Ownership Summary

Zentalis Pharmaceuticals is owned by 99.79% institutional investors, 3.47% insiders. Matrix capital management company, lp is the largest institutional shareholder, holding 19.69% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 6.96% of its assets in Zentalis Pharmaceuticals shares.

ZNTL Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockZentalis Pharmaceuticals99.79%3.47%-3.26%
SectorHealthcare Stocks 46.62%8.13%45.25%
IndustryBiotech Stocks 44.91%7.98%47.11%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Matrix capital management company, lp13.96M19.69%$57.10M
Fmr8.68M12.24%$35.49M
Eventide asset management8.55M12.06%$34.96M
Vanguard group5.65M7.98%$23.13M
Blackrock4.82M6.80%$19.71M
Decheng capital3.07M4.33%$12.56M
State street3.05M4.31%$12.48M
Morgan stanley1.95M2.75%$7.98M
Woodline partners lp1.52M2.14%$6.20M
Bioimpact capital1.45M2.05%$5.93M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mayo clinic187.14K25.27%$765.41K
Decheng capital3.07M3.85%$12.56M
Bioimpact capital1.45M0.92%$5.93M
Tybourne capital management (hk)961.49K0.80%$3.93M
Eventide asset management8.55M0.60%$34.96M
5am venture management490.00K0.45%$2.00M
Matrix capital management company, lp13.96M0.43%$57.10M
Values first advisors74.92K0.18%$306.44K
Boxer capital450.00K0.10%$1.84M
Regency capital management inc.\de29.50K0.08%$120.66K

Top Buyers

HolderShares% AssetsChange
Vanguard group5.65M0.00%1.26M
Decheng capital3.07M3.85%970.86K
Morgan stanley1.95M0.00%913.31K
Two sigma investments, lp1.05M0.01%807.40K
Two sigma advisers, lp796.90K0.01%695.90K

Top Sellers

HolderShares% AssetsChange
Eventide asset management8.55M0.60%-3.03M
Price t rowe associates inc /md/923.90K0.00%-2.57M
Fmr8.68M0.00%-1.97M
Federated hermes482.48K0.00%-1.52M
T. rowe price investment management---1.33M

New Positions

HolderShares% AssetsChangeValue
Y-intercept (hong kong)103.92K0.02%103.92K$425.02K
Virtu financial93.19K0.03%93.19K$381.00K
Norges bank71.53K-71.53K$292.55K
Sherbrooke park advisers41.34K0.03%41.34K$169.08K
Mirae asset global etfs35.59K0.00%35.59K$146.28K

Sold Out

HolderChange
Gamma investing-2.00
Nelson, van denburg & campbell wealth management group-11.00
Riggs asset managment-23.00
Quadrant capital group-24.00
Cwm-39.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2024137-4.86%70,963,212-7.43%990.85%71-13.41%38-5.00%
Jun 30, 20241442.13%76,655,527-9.95%1080.75%825.13%4011.11%
Mar 31, 202414114.63%85,130,1125.09%1200.92%7820.00%3612.50%
Dec 31, 2023123-12.14%81,004,4021.25%1140.89%65-2.99%32-17.95%
Sep 30, 20231402.94%80,005,920-2.95%1130.62%67-27.96%3950.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Eventide Healthcare & Life Sciences I4.95M6.96%-1.63M
Eventide Gilead N3.58M5.04%-1.39M
Vanguard Total Stock Mkt Idx Inv1.89M2.66%-
iShares Russell 2000 ETF1.43M2.01%-3.22K
Fidelity Growth Compy Commingled Pl O1.16M1.63%-
PRIMECAP Odyssey Aggressive Growth1.10M1.55%217.93K
Vanguard Institutional Extnd Mkt Idx Tr896.55K1.26%-
FIAM Small Cap Core CIT Cl B886.80K1.25%11.50K
Fidelity Growth Compy Commingled Pl S881.46K1.24%-280.77K
FIAM Small Cap Core Composite866.20K1.22%289.81K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 04, 2024Vultaggio Vincent Principal Accounting OfficerSell$5.10K
May 31, 2024Gallagher Cam President, Interim CFOSell$114.97K
May 09, 2024HAUSMAN DIANA Chief Medical OfficerSell$42.35K
Feb 12, 2024Epperly Melissa B, Chief Financial OfficerSell$29.44K
Feb 12, 2024Gallagher Cam PresidentSell$13.42K

Insider Transactions Trends

DateBuySell
2024 Q4-1
2024 Q2-2
2024 Q1-6
2023 Q426
2023 Q3-1

ZNTL Ownership FAQ

Who Owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals shareholders are primarily institutional investors at 99.79%, followed by 3.47% insiders and -3.26% retail investors. The average institutional ownership in Zentalis Pharmaceuticals's industry, Biotech Stocks , is 44.91%, which Zentalis Pharmaceuticals exceeds.

Who owns the most shares of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals’s largest shareholders are Matrix capital management company, lp (13.96M shares, 19.69%), Fmr (8.68M shares, 12.24%), and Eventide asset management (8.55M shares, 12.06%). Together, they hold 43.99% of Zentalis Pharmaceuticals’s total shares outstanding.

Does Blackrock own Zentalis Pharmaceuticals?

Yes, BlackRock owns 6.80% of Zentalis Pharmaceuticals, totaling 4.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.71M$. In the last quarter, BlackRock increased its holdings by 172.79K shares, a 3.72% change.

Who is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Mayo clinic is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 25.27% of its assets in 187.14K Zentalis Pharmaceuticals shares, valued at 765.42K$.

Who is the top mutual fund holder of Zentalis Pharmaceuticals shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Zentalis Pharmaceuticals shares, with 6.96% of its total shares outstanding invested in 4.95M Zentalis Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools